Liquid Chromatography and Mass Spectrometry for Biological and Clinical Analyses

Abstract

Mass spectrometry (MS) is a powerful tool to analyze small molecules and proteins in biological and clinical samples. Recently, MS has become an essential technology for an integrative multi-Omics analysis (i.e. metabolomics and proteomics are part of multi-omics along with genomics, epigenomics and transcriptomics) and large-scale proteomics experiments (Kim et al. Proteomics. 2012; Kim et al. Molecular and Cellular Proteomics. 2014.). Because of its applicability, it is now widely used for a variety of biomedical research. For example, one can discover proteome/PTM-based altered networks in perturbed biological conditions by quantitative proteomic analysis while the other could be interested in identifying potential biomarkers/therapeutic targets for diseases. I will first share my experience on a landmark experiment regarding the global human proteome mapping project by focusing on MS-based proteomics and protein modifications along with coverage of basics of MS and proteomic analysis. In addition, I will share recent proteomic results of mass spectrometry and some crucial aspects of proteomic experiments will be also discussed in the context of disease models.